WO1998022499A3 - Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof - Google Patents
Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof Download PDFInfo
- Publication number
- WO1998022499A3 WO1998022499A3 PCT/CA1997/000868 CA9700868W WO9822499A3 WO 1998022499 A3 WO1998022499 A3 WO 1998022499A3 CA 9700868 W CA9700868 W CA 9700868W WO 9822499 A3 WO9822499 A3 WO 9822499A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- arretin
- receptors
- fragments
- nucleic acid
- acid sequences
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4725—Proteoglycans, e.g. aggreccan
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU50442/98A AU5044298A (en) | 1996-11-15 | 1997-11-17 | Neuron and neural tumour growth regulatory system, antibodies thereto and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2,190,418 | 1996-11-15 | ||
CA 2190418 CA2190418A1 (en) | 1996-11-15 | 1996-11-15 | Neuron and neural tumor growth regulatory system, antibodies thereto and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1998022499A2 WO1998022499A2 (en) | 1998-05-28 |
WO1998022499A3 true WO1998022499A3 (en) | 1998-07-30 |
WO1998022499A9 WO1998022499A9 (en) | 1998-09-11 |
Family
ID=4159259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1997/000868 WO1998022499A2 (en) | 1996-11-15 | 1997-11-17 | Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU5044298A (en) |
CA (1) | CA2190418A1 (en) |
WO (1) | WO1998022499A2 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8012930B2 (en) | 1999-12-17 | 2011-09-06 | Curemark, Llc | Methods of treating pervasive development disorders |
US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
US8580522B2 (en) | 2000-11-16 | 2013-11-12 | Curemark, Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
US8673877B2 (en) | 2005-08-30 | 2014-03-18 | Curemark, Llc | Use of lactulose in the treatment of autism |
US8980252B2 (en) | 2011-04-21 | 2015-03-17 | Curemark Llc | Methods of treatment of schizophrenia |
US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
US9061033B2 (en) | 2008-10-03 | 2015-06-23 | Curemark Llc | Methods and compositions for the treatment of symptoms of prion diseases |
US9084784B2 (en) | 2009-01-06 | 2015-07-21 | Curelon Llc | Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces |
US9107419B2 (en) | 2009-01-06 | 2015-08-18 | Curelon Llc | Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces |
US9233146B2 (en) | 2000-08-14 | 2016-01-12 | Curemark, Llc | Method of treating and diagnosing Parkinson's disease and related dysautonomic disorders |
US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3134799A (en) * | 1998-04-16 | 1999-11-08 | Peter Erich Braun | Nevron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration |
US6660831B2 (en) | 2000-08-14 | 2003-12-09 | Joan M. Fallon | Method for diagnosing and treating dysautonomia and other dysautonomic conditions |
WO2006111348A1 (en) * | 2005-04-18 | 2006-10-26 | Abbott Gmbh & Co. Kg | Use of heparin and heparin derivatives for modulating the neurite growth-controlling nogo receptor |
EP2318035B1 (en) | 2008-07-01 | 2019-06-12 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994003601A2 (en) * | 1992-08-03 | 1994-02-17 | New York University | Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan |
WO1994017831A1 (en) * | 1993-02-11 | 1994-08-18 | Erziehungsdirektion Of The Canton Zurich | A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration |
WO1995020397A1 (en) * | 1994-01-27 | 1995-08-03 | New York University | Phosphacan, nucleic acids encoding thereof and antibodies thereto |
WO1995022344A1 (en) * | 1994-02-21 | 1995-08-24 | Mcgill University | Therapeutic use of myelin-associated glycoprotein (mag) |
WO1995026201A1 (en) * | 1994-03-28 | 1995-10-05 | La Jolla Cancer Research Foundation | Brevican, a glial cell proteoglycan |
WO1996032476A1 (en) * | 1995-04-13 | 1996-10-17 | Mount Sinai Hospital Corporation | Modulator of neuronal cell response to inhibition by cns myelin |
WO1996032959A1 (en) * | 1995-04-19 | 1996-10-24 | Acorda Therapeutics | Cns neurite outgrowth modulators, and compositions, cells and methods embodying and using same |
-
1996
- 1996-11-15 CA CA 2190418 patent/CA2190418A1/en not_active Abandoned
-
1997
- 1997-11-17 AU AU50442/98A patent/AU5044298A/en not_active Abandoned
- 1997-11-17 WO PCT/CA1997/000868 patent/WO1998022499A2/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994003601A2 (en) * | 1992-08-03 | 1994-02-17 | New York University | Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan |
WO1994017831A1 (en) * | 1993-02-11 | 1994-08-18 | Erziehungsdirektion Of The Canton Zurich | A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration |
WO1995020397A1 (en) * | 1994-01-27 | 1995-08-03 | New York University | Phosphacan, nucleic acids encoding thereof and antibodies thereto |
WO1995022344A1 (en) * | 1994-02-21 | 1995-08-24 | Mcgill University | Therapeutic use of myelin-associated glycoprotein (mag) |
WO1995026201A1 (en) * | 1994-03-28 | 1995-10-05 | La Jolla Cancer Research Foundation | Brevican, a glial cell proteoglycan |
WO1996032476A1 (en) * | 1995-04-13 | 1996-10-17 | Mount Sinai Hospital Corporation | Modulator of neuronal cell response to inhibition by cns myelin |
WO1996032959A1 (en) * | 1995-04-19 | 1996-10-24 | Acorda Therapeutics | Cns neurite outgrowth modulators, and compositions, cells and methods embodying and using same |
Non-Patent Citations (4)
Title |
---|
BODE-LESNIEWSKA ET AL.: "Distribution of the large aggregating proteoglycan versican in adult human tissues", THE JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY, vol. 44, no. 4, - April 1996 (1996-04-01), pages 303 - 312, XP002062505 * |
ESKO J.: "GENETIC ANALYSIS OF PROTEOGLYCAN STRUCTURE, FUNCTION AND METABOLISM", CURRENT OPINION IN CELL BIOLOGY, vol. 3, 1991, pages 805 - 816, XP002062506 * |
FRIEDLANDER ET AL.: "THE NEURONAL CHONDROITIN SULFATE PROTEOGLYCAN NEUROCAN BINDS TO THE NEURAL CELL ADHESION MOLECULES Ng-CAM/L1/NILE AND N-CAM, AND INHIBITS NEURONAL ADHESION AND NEURITE OUTGROWTH", THE JOURNAL OF CELL BIOLOGY, vol. 125, no. 3, 1994, pages 669 - 680, XP002062504 * |
SCHWAB M E ET AL: "INHIBITORS OF NEURITE GROWTH", ANNUAL REVIEW OF NEUROSCIENCE, vol. 16, 1 January 1993 (1993-01-01), pages 565 - 595, XP000576555 * |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8613918B2 (en) | 1999-12-17 | 2013-12-24 | Curemark Llc | Method for treating pervasive development disorders |
US8012930B2 (en) | 1999-12-17 | 2011-09-06 | Curemark, Llc | Methods of treating pervasive development disorders |
US8105584B2 (en) | 1999-12-17 | 2012-01-31 | Curemark Llc | Method for treating pervasive development disorders |
US8815233B2 (en) | 1999-12-17 | 2014-08-26 | Curemark Llc | Method for treating pervasive development disorders |
US9233146B2 (en) | 2000-08-14 | 2016-01-12 | Curemark, Llc | Method of treating and diagnosing Parkinson's disease and related dysautonomic disorders |
US8921054B2 (en) | 2000-11-16 | 2014-12-30 | Curemark, Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US9377459B2 (en) | 2000-11-16 | 2016-06-28 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US8580522B2 (en) | 2000-11-16 | 2013-11-12 | Curemark, Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US9345721B2 (en) | 2005-08-30 | 2016-05-24 | Curemark, Llc | Use of lactulose in the treatment of autism |
US8673877B2 (en) | 2005-08-30 | 2014-03-18 | Curemark, Llc | Use of lactulose in the treatment of autism |
US9023344B2 (en) | 2008-03-13 | 2015-05-05 | Curemark, Llc | Method of treating toxemia |
US9408895B2 (en) | 2008-03-13 | 2016-08-09 | Curemark, Llc | Method of treating pregnancy-induced hypertension |
US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
US8486390B2 (en) | 2008-04-18 | 2013-07-16 | Curemark Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
US9017665B2 (en) | 2008-04-18 | 2015-04-28 | Curemark, Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US8318158B2 (en) | 2008-04-18 | 2012-11-27 | Curemark, Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
US9061033B2 (en) | 2008-10-03 | 2015-06-23 | Curemark Llc | Methods and compositions for the treatment of symptoms of prion diseases |
US9084784B2 (en) | 2009-01-06 | 2015-07-21 | Curelon Llc | Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces |
US9107419B2 (en) | 2009-01-06 | 2015-08-18 | Curelon Llc | Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces |
US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
US9415014B2 (en) | 2009-04-13 | 2016-08-16 | Curemark, Llc | Enzyme delivery systems and methods of preparation and use |
US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
US8980252B2 (en) | 2011-04-21 | 2015-03-17 | Curemark Llc | Methods of treatment of schizophrenia |
US9492515B2 (en) | 2011-04-21 | 2016-11-15 | Curemark, Llc | Method of treatment of schizophreniform disorder |
Also Published As
Publication number | Publication date |
---|---|
CA2190418A1 (en) | 1998-05-15 |
AU5044298A (en) | 1998-06-10 |
WO1998022499A2 (en) | 1998-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998022499A3 (en) | Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof | |
WO1998031806A3 (en) | Fc receptors and polypeptides | |
WO1998030694A3 (en) | TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b) | |
DK0939804T3 (en) | Neutrokine-alpha | |
WO2001055448A8 (en) | Nucleic acids, proteins, and antibodies | |
WO1997033909A3 (en) | Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer | |
EP1439230A3 (en) | Human transmembrane protein TMP-2 gene | |
WO1998031818A3 (en) | Tace-like and matrilysin-like polypeptides | |
AU6250098A (en) | Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l) | |
WO2001054472A8 (en) | Nucleic acids, proteins, and antibodies | |
CA2174971A1 (en) | Neural Axon Outgrowth Modulators | |
WO2000020447A3 (en) | Polynucleotides coding for secreted polypeptides, some having similarity to syncollin or claudin or cytokine, their therapeutic uses | |
WO1998011234A3 (en) | Human protein kinases | |
WO1999033870A3 (en) | Human regulatory proteins | |
AU1239997A (en) | Polypeptides corresponding to the amino acid sequences of proteins p57 or p9.5 of Borna disease virus, nucleic acid fragments coding therefore and their use for diagnostic and immunization purposes | |
WO2000061774A3 (en) | Bone morphogenic proteins | |
WO2000044898A3 (en) | Novel agouti and agouti-related peptide analogs | |
WO2000065054A3 (en) | Human membrane-associated proteins | |
WO2001055168A8 (en) | Nucleic acids, proteins and antibodies | |
ATE300554T1 (en) | CONNECTIVE TISSUE GROWTH FACTOR 3. | |
WO2005003299A3 (en) | Polynucleotides encoding novel guanylate binding proteins (gbp's) | |
EP0816498A3 (en) | Excitatory amino acid receptor protein and related nucleic acid compounds | |
WO2001046256A3 (en) | Vesicle trafficking proteins | |
WO2001000662A3 (en) | The use of human fgh-8 polypeptides as neurotrophic agents | |
WO2000026243A3 (en) | Transmembrane 4 proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
COP | Corrected version of pamphlet |
Free format text: PAGES 1/14-6/14 AND 10/14-14/14, DRAWINGS, REPLACED BY NEW PAGES 1/14-6/14 AND 10/14-14/14; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |